EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Rationale and Design of the InsightPFA Trial: A Prospective, Multicenter, Randomized Controlled Trial of the Irreversible Electroporation‐Based Pulsed Field Ablation Versus Radiofrequency Ablation in Chinese Patients With Symptomatic Paroxysmal Atrial Fibrillation

Weidong Lin iD, Sijia Pu iD, Huimin Chu, Dong Chang, Xiaomeng Yin, Yuegang Wang, Yizhou Xu, Shaolong Li iD, Jian Yang, Wenqing Zhu iD, Songnan Li, Weidong Gao und 4 weitere

Journal of Cardiovascular Electrophysiology · 2025

DOI: 10.1111/jce.16573 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2025. Verfasst von Weidong Lin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guan…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Electroporation, Pulmonary Veins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: This study was supported by Insight Medtech Co. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pulsed field ablation (PFA) is gaining recognition as a nonthermal, tissue‐specific technique for the treatment of atrial fibrillation (AF). The preclinical evaluation of the investigated novel PFA system from Insight Medtech Co. Ltd has demonstrated feasibility, safety, and 30‐day efficacy for pulmonary vein isolation (PVI) in the swine model. We are currently conducting a randomized controlled trial to compare the PFA directly with ablation‐index (AI)‐guided radiofrequency ablation (RFA) for PVI. Methods and Results The InsightPFA trial is a prospective, multicenter, randomized controlled trial to compare the effectiveness and safety of PFA versus RFA for PVI in Chinese patients with symptomatic paroxysmal AF. Two hundred and ninety‐two patients diagnosed with symptomatic paroxysmal AF will be randomly assigned to either the PFA group or the RFA group in a 1:1 ratio. All subjects will undergo PVI using PFA or AI‐guided RFA and be followed up to 12 months. The primary endpoint is defined as freedom from any episodes of AF/AFL/AT without Class I or III antiarrhythmic drugs during the 9‐month follow‐up period after a 90‐day blank period. The secondary endpoints of effectiveness include acute treatment success and procedural data. The safety evaluation includes a composite of death, stroke and transient ischemic attack, procedure‐related complications, device‐related adverse events, and serious adverse events. A noninferiority comparison will be conducted between the novel PFA system and the existing RFA system in terms of both effectiveness and safety.

Conclusions

This trial aims to determine whether the InsightPFA for PVI is as effective and safe as standard RFA in the treatment of symptomatic paroxysmal AF. Trial Registration: https://www.clinicaltrials.gov/study/NCT06014996 ; NCT06014996.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationElectroporationPulmonary VeinsAdultAgedFemaleHumansMaleMiddle AgedAction PotentialsChinaHeart RateMulticenter Studies as TopicProspective StudiesRandomized Controlled Trials as TopicRecurrenceTime FactorsTreatment OutcomeEast Asian PeopleEquivalence Trials as Topic

Stichwörter der Autor:innen

atrial fibrillationcatheter ablationpulmonary vein isolationpulsed field ablationrandomized controlled trial

Autor:innen und Institutionen

  • Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • School of Medicine, South China University of Technology, Guangzhou, China.
  • First Affiliated Hospital of Ningbo University, Ningbo, China.
  • Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, China.
  • Institute of Cardiovascular Diseases, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
  • Nanfang Hospital, Southern Medical University, Guangzhou, China.

ORCID-Profile: Weidong Lin, Sijia Pu, Shaolong Li, Wenqing Zhu, Chenyang Jiang

Förderung

  • This study was supported by Insight Medtech Co. Ltd.

Zitieren

APA

Lin, W., Pu, S., Chu, H., Chang, D., Yin, X., Wang, Y., Xu, Y., Li, S., Yang, J., Zhu, W., Li, S., Gao, W., Chen, Y., Xu, D., Jiang, C., & Xue, Y. (2025). Rationale and Design of the InsightPFA Trial: A Prospective, Multicenter, Randomized Controlled Trial of the Irreversible Electroporation‐Based Pulsed Field Ablation Versus Radiofrequency Ablation in Chinese Patients With Symptomatic Paroxysmal Atrial Fibrillation. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16573

Vancouver

Lin W, Pu S, Chu H, Chang D, Yin X, Wang Y, et al. Rationale and Design of the InsightPFA Trial: A Prospective, Multicenter, Randomized Controlled Trial of the Irreversible Electroporation‐Based Pulsed Field Ablation Versus Radiofrequency Ablation in Chinese Patients With Symptomatic Paroxysmal Atrial Fibrillation. Journal of Cardiovascular Electrophysiology. 2025. doi:10.1111/jce.16573

BibTeX
@article{Lin2025,
  author = {Lin, Weidong and Pu, Sijia and Chu, Huimin and Chang, Dong and Yin, Xiaomeng and Wang, Yuegang and Xu, Yizhou and Li, Shaolong and Yang, Jian and Zhu, Wenqing and Li, Songnan and Gao, Weidong and Chen, Yanbo and Xu, Dong and Jiang, Chenyang and Xue, Yumei},
  title = {Rationale and Design of the InsightPFA Trial: A Prospective, Multicenter, Randomized Controlled Trial of the Irreversible Electroporation‐Based Pulsed Field Ablation Versus Radiofrequency Ablation in Chinese Patients With Symptomatic Paroxysmal Atrial Fibrillation},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2025},
  doi = {10.1111/jce.16573}
}
Kostenlos starten →